Schonfeld Strategic Advisors’s Virax Biolabs VRAX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio VRAX Stock Details VRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-146	Closed	-$115K	–	3045
2022 Q3	$115K	Buy	+146	New	+$241K	﹤0.01%	2513

Other funds holding VRAX

Kapitalo Investimentos Sao Paulo, Brazil $531M AUM 25.72% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RAM

Riggs Asset Management Dallas, Pennsylvania $486M AUM 59.08% 1-Year Est. Return

Schonfeld Strategic Advisors's VRAX Position: Q4 2022 in Review

Schonfeld Strategic Advisors sold out of Virax Biolabs (VRAX) in Q4 2022, closing a stake of 146 shares — an estimated $115K sold.

Schonfeld Strategic Advisors first reported a position in VRAX in Q3 2022 and held it in 1 quarter. The position peaked at $115K in Q3 2022. 7 funds tracked by Wall St. Rank hold VRAX as of Q4 2022.

Schonfeld Strategic Advisors reported no remaining Virax Biolabs position as of Q4 2022 after selling out during the quarter.
Schonfeld Strategic Advisors sold 146 Virax Biolabs shares in Q4 2022, an estimated $115K.
Schonfeld Strategic Advisors first reported a position in Virax Biolabs in Q3 2022 and held it in 1 quarter.
Schonfeld Strategic Advisors's Virax Biolabs position peaked at $115K in Q3 2022.
7 funds tracked by Wall St. Rank held Virax Biolabs as of Q4 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.